Novo Nordisk to promote new obesity drug in the US

Novo Nordisk to promote new obesity drug in the US

Novo Nordisk, a pharmaceutical group from Denmark, plans to utilize its 500 out of 3000 strong personnel on sales in the United States to market its \"new obesity drugs,\" Jakob Riis, Executive Vice President, told Reuters last Monday..